Source:http://linkedlifedata.com/resource/pubmed/id/17214367
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6C
|
| pubmed:dateCreated |
2007-1-11
|
| pubmed:abstractText |
The membrane cofactor protein CD46 represents a complement inhibitor, which protects autologous cells from complement - mediated cytotoxicity. CD46 may exhibit the potential to protect tumor cells from the immune responses of the host. The present study aimed to evaluate the prognostic significance of CD46 expression in ovarian cancers.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0250-7005
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
26
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
4943-8
|
| pubmed:meshHeading |
pubmed-meshheading:17214367-Antigens, CD46,
pubmed-meshheading:17214367-Female,
pubmed-meshheading:17214367-Humans,
pubmed-meshheading:17214367-Immunohistochemistry,
pubmed-meshheading:17214367-Middle Aged,
pubmed-meshheading:17214367-Ovarian Neoplasms,
pubmed-meshheading:17214367-Paraffin Embedding,
pubmed-meshheading:17214367-Prognosis,
pubmed-meshheading:17214367-Retrospective Studies
|
| pubmed:articleTitle |
CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients.
|
| pubmed:affiliation |
Institute of Pathology, Charité Campus Mitte, D-10117 Berlin, Germany.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|